# The Effect of Dopamine on Diabetic Retinopathy

> **NCT02706977** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 60 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Low Dose Sinemet CR
- **DRUG:** High Dose Sinemet CR
- **DEVICE:** RETeval Electroretinogram (ERG) Testing
- **OTHER:** Contrast Sensitivity Testing
- **OTHER:** Visual Acuity Testing

## Key facts

- **NCT ID:** NCT02706977
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-08-15
- **Final completion:** 2019-08-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706977, "The Effect of Dopamine on Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02706977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*